2013
DOI: 10.1016/j.critrevonc.2012.12.003
|View full text |Cite
|
Sign up to set email alerts
|

Revisiting bleomycin from pathophysiology to safe clinical use

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
61
0
4

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 99 publications
(65 citation statements)
references
References 74 publications
0
61
0
4
Order By: Relevance
“…Bleomycin‐induced adverse effects include GI disorders, myelosuppression, cutaneous reactions, and pulmonary toxicity, in particular severe and life‐threatening lung fibrosis (Froudarakis et al. 2013; Della Latta et al. 2015).…”
Section: Introductionmentioning
confidence: 99%
“…Bleomycin‐induced adverse effects include GI disorders, myelosuppression, cutaneous reactions, and pulmonary toxicity, in particular severe and life‐threatening lung fibrosis (Froudarakis et al. 2013; Della Latta et al. 2015).…”
Section: Introductionmentioning
confidence: 99%
“…Bleomycin (BLM) is anti-tumor antibiotic glycopeptide produced by actinobacterium Streptomyces verticillu [4]. Cytotoxic activity of BLM is through oxidation in deoxyribose of thymidylate and other nucleotides, which produced single-strand and double-strand breaks in DNA, chromosomal aberration, gaps, fragments and translocation [4].…”
Section: Introductionmentioning
confidence: 99%
“…6,15,16 A bleomicina resulta em um distúrbio restritivo associado a redução da difusão de monóxido de carbono, CPT, capacidade vital e do VEF1 em cerca de 50% dos casos. 17,18 A toxicidade pulmonar pela bleomicina é na maioria das vezes advinda das doses acumulativas, tendo sido evidenciado que doses inferiores a 300 mg raramente causam toxicidade pulmonar e à medida que a dose excede 400 mg há risco de desenvolvimento de toxicidade. …”
Section: Discussionunclassified